NCT06881537View on ClinicalTrials.gov

CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2028

Conditions
Locally Recurrent Colorectal Cancer
Interventions
DRUG

Capecitabine

Capecitabine is given orally at 1000mg / m² twice a day from day1-14 every 3 weeks for 4 cycles

DRUG

Oxaliplatin

Oxaliplatin is given by intravenous infusion at 130mg / m² on Day 1 every 3 weeks for 4 cycles

DRUG

Bevacizumab

Bevacizumab is given intravenously at 7.5mg/kg on day 1 every 3 weeks for 4 cycles

DRUG

Tislelizumab

Tislelizumab is given intravenously at 200 mg on day 1 every 3 weeks for 4 cycles

Trial Locations (1)

Unknown

RECRUITING

Shanghai Changzheng Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Changzheng Hospital

OTHER